相关实验视频

Updated: Jun 26, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

在癌症中对PD-1/PD-L1的调节机制

Xin Lin^1,2,3,4, Kuan Kang^1,2,3,4, Pan Chen¹

¹NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, 410013, Hunan, China.

Molecular cancer

|May 18, 2024

概括

癌细胞使用PD-1/PD-L1等免疫检查点来逃避免疫反应. 用抗体阻止这种途径可以恢复抗瘤免疫力,为癌症治疗提供新的治疗策略.

科学领域:

免疫学免疫学免疫学
在瘤学瘤学.
癌症研究癌症研究

背景情况:

免疫逃避是癌症进展的关键因素,癌细胞利用免疫检查点途径来抑制抗瘤反应.
编程细胞死亡蛋白1 (PD-1) 和其连接物 (PD-L1) 是关键的免疫检查点分子,可以负面调节T细胞活动并促进免疫耐受性.
癌细胞利用PD-1/PD-L1轴实现免疫逃生,阻碍身体对瘤生长的自然防御.

研究的目的:

综合审查PD-1/PD-L1信号传导在人类自身免疫性疾病和癌症中的作用.
总结调控PD-1和PD-L1在癌症中的表达和活性的调控机制.
审查抗PD-1/PD-L1疗法的临床进展及其用于增强抗瘤免疫力的组合策略.

主要方法:

对癌症和自身免疫性疾病中PD-1/PD-L1信号传递现有文献的综述.
对PD-1/PD-L1.1的遗传,表观遗传,转录后和翻译后调节机制的分析.
关于PD-1/PD-L1阻断疗法的临床试验数据的摘要.

主要成果:

PD-1/PD-L1通路是癌症免疫逃避的一个重要机制.
各种调节机制控制癌细胞中的PD-1/PD-L1表达和功能.
用抗体阻断PD-1/PD-L1,有效地恢复T细胞活性,增强抗瘤免疫力,显示临床成功.

结论:

针对PD-1/PD-L1轴是癌症治疗的一个有前途的治疗策略.
了解PD-1/PD-L1的调节机制可以导致新型瘤标志物的发展.
涉及PD-1/PD-L1阻塞的组合疗法有可能改善抗瘤效果并克服治疗耐药性.

关键词:

组合疗法是一种联合疗法.在PD-1中使用PD-1.在PD-L1中.监管机制监管机制瘤免疫系统的免疫力

更多相关视频

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

相关概念视频

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Interactions Between Signaling Pathways

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

The Intrinsic Apoptotic Pathway

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Negative Regulator Molecules

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.